Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong kong

Hong Kong Medical Journal

Volumn 9, Issue 3, 2003, Pages 179-185

  Leung, C S ^a   Tam, K M ^a  

^a YAN CHAI HOSPITAL   (Hong Kong)

Author keywords

Anticoagulants; Aspirin; Atrial fibrillation; Chinese; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HONG KONG; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 0037561864     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
2. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
3. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA 2000;284:1670-6.
4. Yu TS, Tse LA, Wong TW, Wong SI. Recent trends of stroke mortality in Hong Kong: age, period, cohort analyses and the implications. Neuroepidemiology 2000;19:265-74.
5. Hospital Authority Census and Statistics Department Data. Hospital Authority website: http://www.ha.org.hk. Accessed 4 October 2002.
6. Woo J, Lau EM. Risk factors predisposing to stroke in an elderly Chinese population - a longitudinal study. Neuroepidemiology 1990;9:131-4.
7. Yip PK, Jeng JS, Lee TK, et al. Subtypes of ischemic stroke. A hospital-based stroke registry in Taiwan (SCAN-IV). Stroke 1997;28: 2507-12.
8. Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996;89: 127-35.
9. Yu CM, Chan TY, Tsoi WC, Sanderson JE. Heparin therapy in the Chinese - lower doses are required. QJM 1997;90:535-43.
10. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001;103:163-82.
11. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(1 Suppl): 194S-206S.
12. Lip GY. How would I manage a 60-year-old woman presenting with atrial fibrillation? Proc R Coll Physicians Edinb 1999;29:301-6.
13. Di Minno G, Tufano A, Cerbone AM. Antithrombotic drugs for older subjects. Guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG). Nutr Metab Cardiovasc Dis 2001;11:41-62.
14. Algra A, Koudstaal A, Koudstaal PJ. How do we prevent thromboembolism in atrial fibrillation? Secondary prevention. Proc R Coll Physicians Edinb 1999;29(Suppl 6):27S-9S.
15. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
16. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
17. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B, Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.
18. Chenhsu RY, Chiang SC, Chou MH, Lin MF. Long-term treatment with warfarin in Chinese population. Ann Pharmacother 2000;34:1395-401.
19. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-95.
20. Cao X, Wang S, Jiang L, Liu L, Huang H, Lu Z. Embolic events in 93 elderly Chinese patients with atrial fibrillation. Chin Med J (Engl) 2000;113:320-3.
21. Woo J, Lau E, Kay R. Elderly subjects aged 70 years and above have different risk factors for ischemic and hemorrhagic strokes compared to younger subjects. J Am Geriatr Soc 1992;40:124-9.
22. Albers GW, Yim JM, Belew KM, et al. Status of anfithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-6.
23. Brass LM, Krumholz HM, Scinto JD, Mathur D, Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998;158:2093-100.
24. Jackson SL, Peterson GM, Vial JH, Daud R, Ang SY. Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J 2001;31:329-36.
25. Lip GY, Bawden L, Hodson R, Rutland E, Snatchfold J, Beevers DG. Atrial fibrillation amongst the Indo-Asian general practice population. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 1998;65:187-92.
26. Tomita F, Kohya T, Sakurai M, et al. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn Circ J 2000;64:653-8.
27. Lok NS, Lau CP. Presentation and management of patients admitted with atrial fibrillation: a review of 291 cases in a regional hospital. Int J Cardiol 1995;48:271-8.
28. Smith NL, Psaty BM, Furberg CD, et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999;159:1574-8.
29. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999;137:307-12.
30. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000;85:568-72.
31. Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice-based study. Br J Gen Pract 2001;51:884-6,889-91.
32. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119(1 Suppl):22S-38S.
33. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch Intern Med 1984;144:1966-8.
34. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001;161:1443-7.
35. Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000;31:2106-11.
36. Segal JB, McNamara RL, Miller MR et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev 2001;(1):CD001938.
37. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958-64.
38. Cheung RT, Li LS, Tsang KL, Leung KP. Stroke prevention in atrial fibrillation among Hong Kong Chinese. Cerebrovasc Dis 2001;11:353-4.